There is now abundant evidence (with a 15-year hiatus) that the aforementioned observations regarding the bradykinin-forming pathway are seen in patients with Alzheimer’s disease, with some evidence that activation is more readily observed in more severely affected subjects. This evidence concerns the gene KNG1 and early-onset autosomal dominant Alzheimer disease.